Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,974.00
Bid: 1,974.00
Ask: 1,976.00
Change: -26.00 (-1.30%)
Spread: 2.00 (0.101%)
Open: 2,008.00
High: 2,012.00
Low: 1,958.00
Prev. Close: 2,000.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS: Tesco And Sainsbury's Beaten By Morrisons

Tue, 30th Jun 2015 10:17

LONDON (Alliance News) - The following stocks are amongst the biggest risers and fallers within the main London indices midday Tuesday.
-------
FTSE 100 WINNERS
-------
Hikma Pharmaceuticals, up 0.6%. The pharmaceutical company is among bidders for Boehringer Ingelheim GmbH's Roxane Labs business in the US, Bloomberg reported citing people familiar with the matter. The report said that other potential buyers for the generic pharmaceutical unit, which may fetch as much as EUR2 billion or USD2.2 billion, include Mallinckrodt and Perrigo Co. A decision on the winner could be made within weeks, though the German drugmaker may still choose to keep the asset.
-------
FTSE 100 LOSERS
-------
Tesco, down 2.1%, J Sainsbury, down 1.6%. Sainsbury's and Tesco came in joint second place out of the big four in the Kantar Worldpanel UK's grocery market data published on Tuesday, both experiencing an annual sales decline of 1.3% in the period. Sainsbury's sales were at GBP4.18 billion, down from GBP4.23 billion a year before, as its market share declined to 16.5% from 16.7%, while Tesco sales fell to GBP7.24 billion from GBP7.34 billion, as its market share dropped to 28.6% from 28.9%. Wm Morrison Supermarkets, whose shares are down 0.3%, was for the second month in a row the only member of the big four UK supermarkets to increase sales.
-------
FTSE 250 WINNERS
-------
Home Retail Group, up 3.5%. Morgan Stanley upgraded the owner of the Argos general merchandise chain and the Homebase DIY chain to Overweight from Equal Weight, lifting its price target to 180 pence from 170p.

St Modwen Properties, up 2.1%. The regeneration property company said it expects to see positive momentum continue into the second half of its financial year after reporting a jump in pretax profit for the first. It made a GBP177.6 million pretax profit in the six months ended May 31, compared with GBP48.6 million in the corresponding period of the prior year. St. Modwen also was upgraded by Numis to Buy from Add, and its price target lifted to 570p from 471p.
-------
FTSE 250 LOSERS
-------
Northgate, down 7.4%. The commercial light vehicle rental company said pretax profit surged in its 2015 financial year as revenue rose across both hire and sale business, prompting the company to hike its dividend payout by nearly half. However, N+1 Singer retains its Hold recommendation due to currency headwinds and depreciation. Meanwhile, Numis downgrades the stock to Hold from Add, raising its price target to 640p from 612p. Though saying Northgate results were "impressive", Numis also notes forex headwinds and depreciation as reasons to be cautious.

Ocado Group, down 1.7%. The online grocery business reported a small decline in profit in the first half of its financial year even though sales grew, as it booked costs associated with investments, distribution and administration. It said pretax profit in the 24 weeks ended May 17 slipped to GBP7.2 million from GBP7.5 million in the same period the year before, despite revenue rising 18% to GBP507.7 million from GBP429.7 million. Shore Capital said it retains a Sell recommendation on the company after the results.

Ultra Electronics, down 1.4%. Berenberg downgraded the defence company to Sell from Hold, cutting its price target to 1,600p from 1,600p.
-------
AIM ALL-SHARE WINNERS
-------
Taihua, up 17%. The chinese pharmaceutical company doubled its pretax profit in 2014 despite lower revenue, thanks primarily to robust sales of its Forsythia product and due to lower inventory provisioning. It said its pretax profit for the year was CNY6.6 million, up from CNY3.3 million a year earlier, despite revenue falling to CNY50.9 million from CNY52.3 million.

Mountfield Group, up 7.3%. The company said the review of its Mountfield Building Group business is already producing measurable benefits. It said the review of the building group business led to a change in focus from carrying out projects with a high risk, fixed-price nature to targeting works directly awarded by clients, which offer lower risks and better margins. Those changes have resulted in a significantly improved trading performance for the division in the year to date, Mountfield said.
-------
AIM ALL-SHARE LOSERS
-------
William Sinclair Holdings, down 27%. The company, which makes gardening products, said it is arranging meetings with investors to test demand for a sizeable share placing, while warning that progress on funding is required in the next few weeks. It said it is still considering its strategic options, with the process now beyond the first phase and the company receiving numerous signs of interest, following a review of the business.

Strat Aero, down 22%. The company said its revenue in the first half of 2015 has been weaker than expected as it published its 2014 results. Strat Aero said revenue in the year to date has been "considerably lower" than its expectations and said it was difficult to predict how the growth of the Unmanned Aerial Vehicle, or drone, market will pan out. It said its pretax loss for the year to December 31 was USD1.2 million, on revenue of USD630,685. No comparable figures were provided.

Sweett Group, down 15%. The construction and building consultancy scrapped its dividend after swinging to a loss in its 2015 financial year, hit by goodwill charges and a decline in revenue. It swung to a pretax loss of GBP1.1 million in the year to the end of March, compared to a GBP2.8 million profit a year earlier, due primarily to a GBP2.4 million goodwill impairment charge it booked related to a probe by the UK's Serious Fraud Office into the conduct of a former employee of its Cyril Sweet International subsidiary in the Middle East.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
24 Feb 2022 10:31

TOP NEWS: Hikma Pharmaceutical records revenue growth and lifts payout

(Alliance News) - Hikma Pharmaceutical PLC on Thursday reported full-year revenue growth on a "strong" performance by its three business segments and lifted its shareholder payout.

Read more
24 Feb 2022 07:58

Hikma Pharmaceutical delivers year of 'solid growth' and 'strategic momentum'

(Sharecast News) - Drugmaker Hikma Pharmaceutical said on Thursday that it had delivered another successful year of "solid growth and continued strategic momentum", with both revenue and operating profits improving year-on-year.

Read more
24 Feb 2022 07:50

LONDON MARKET PRE-OPEN: Share buybacks for Lloyds Banking and Hikma

(Alliance News) - Stock prices in London are seen opening sharply lower, with the FTSE 100 called down almost 200 points, amid fear of a full-scale war in eastern Europe after Russia announced the beginning of a military operation in Ukraine.

Read more
17 Feb 2022 16:08

UK earnings, trading statements calendar - next 7 days

Friday 18 February  
NatWest Group PLCFull Year Results
Pod Point Group Holdings PLCFull Year Results
Segro PLCFull Year Results
TBC Bank Group PLCFull Year Results
Monday 21 February 
Bank of Cyprus Holdings PLCFull Year Results
Dechra Pharmaceuticals PLCHalf Year Results
Finsbury Food Group PLCHalf Year Results
Sylvania Platinum LtdHalf Year Results
Tristel PLCTrading Statement
Wilmington PLCHalf Year Results
Tuesday 22 February 
Antofagasta PLCFull Year Results
Bank of Georgia Group PLCFull Year Results
Benchmark Holdings PLCQ1 Results
Blancco Technology Group PLCHalf Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Coca-Cola HBC AGFull Year Results
Hargreaves Lansdown PLCHalf Year Results
HSBC Holdings PLCFull Year Results (at 0400 GMT)
InterContinental Hotels Group PLCFull Year Results
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Smith & Nephew PLCFull Year Results
Springfield Properties PLCHalf Year Results
Synectics PLCFull Year Results
Transense Technologies PLCHalf Year Results
Wednesday 23 February 
Aston Martin Lagonda Global Holdings PLCFull Year Results
Barclays PLCFull Year Results
Capital & Counties Properties PLCFull Year Results
CAP-XX LtdHalf Year Results
Georgia Capital PLCFull Year Results
International Personal Finance PLCFull Year Results
Irish Residential Properties REIT PLCFull Year Results
Metro Bank PLCFull Year Results
Hochschild Mining PLCFull Year Results
Photo-Me International PLCFull Year Results
Rio Tinto PLCFull Year Results
Seraphim Space Investment Trust PLCHalf Year Results
Ted Baker PLCTrading Statement
Unite Group PLCFull Year Results
Thursday 24 February 
Anglo American PLCFull Year Results
BAE Systems PLCFull Year Results
Centrica PLCFull Year Results
Conduit Holdings LtdFull Year Results
Derwent London PLCFull Year Results
Drax Group PLCFull Year Results
Genus PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Inchcape PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Rathbone Group PLCFull Year Results
Ricardo PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
Serco Group PLCFull Year Results
Spectris PLCFull Year Results
St James's Place PLCFull Year Results
Tremor International LtdFull Year Results
WPP PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
9 Feb 2022 09:48

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

Read more
3 Feb 2022 09:12

Hikma completes acquisition of Teligent's Canadian assets

Hikma completes acquisition of Teligent's Canadian assets

Read more
17 Jan 2022 09:01

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 09:00

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 07:49

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

Read more
17 Jan 2022 07:08

Hikma buys Teligent Canadian assets for $47.75m

(Sharecast News) - Hikma Pharmaceuticals on Monday said it had agreed to buy the Canadian assets of Teligent for $45.75m after the US firm filed for Chapter 11 bankruptcy last year.

Read more
10 Jan 2022 07:44

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

Read more
10 Jan 2022 07:24

Hikma launches new US injectables unit

(Sharecast News) - Hikma Pharmaceuticals on Monday said it was expanding its injectables business with the launch of a new outsourced sterile compounding business in the US.

Read more
21 Dec 2021 15:55

Arecor flags milestone payment from Hikma in first half of next year

(Sharecast News) - Biopharmaceutical company Arecor Therapeutics updated the market on its ongoing exclusive agreement with Hikma Pharmaceuticals to co-develop a new, ready-to-use injectable medicine on Tuesday.

Read more
9 Dec 2021 09:25

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Read more
9 Dec 2021 08:32

Hikma strikes exclusive license agreement with Richter for denosumab

(Sharecast News) - Drugmaker Hikma Pharmaceuticals has entered into an exclusive license agreement with Gedeon Richter to commercialise the latter's denosumab products in the US.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.